Table 6 Prognostic factors for OS of patients who underwent radical surgery

From: A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer

  Univariate analysis Multivariate analysis
Variable No. of patients ( n =67) (%) MST (months) P -value HR 95% CI P -value
Gender    0.8070    
 Male 49 (73.1) 76.0     
 Female 18 (26.8)   0.864 0.312–2.395 0.779
Location    0.1022    
 Upper 10 (14.9) 76.0     
 Middle 22 (32.8) 63.5   0.503 0.111–2.289 0.374
 Lower 33 (49.2)   0.473 0.114–1.963 0.303
 Diffuse 2(3.0) 13.0   2.768 0.387–19.799 0.310
Pre-chemotherapy TNM    0.0705 1.25 0.468–3.339 0.656
 IB 5 (7.5)     
 II 49 (73.1)     
 III 13 (19.4) 19.0     
Lauren classification    0.0036    
 Intestinal 23 (34.3)     
 Diffuse 37 (55.2) 38.0   9.963 1.937–51.235 0.006
 Mixed 7 (10.4) 22.0   8.890 1.157–68.323 0.036
Local infiltration    0.0214    
 Yes 4 (6.0) 16.2     
 No 63 (94.0)   0.584 0.141–2.416 0.458
Pathologic T downstaging    0.3243    
 Yes 22 (32.8)     
 No 45 (67.2) 76.0   1.088 0.377–3.141 0.876
Pathologic N downstaging    0.0171    
 Yes 17 (25.4)     
 No 50 (74.6) 54.0   6.532 0.088–3.220 0.492
ypTNM    <0.0001 4.045 1.429–11.446 0.008
 0+I 11 (16.4)     
 II 30 (44.7)     
 III 26 (38.8) 17.5     
Pathological evaluation standard of JCGC    0.0292    
 G3+G2 20 (29.9)     
 G1+G0 47 (70.1) 76.0   1.127 0.321–3.955 0.852
Graded histologic response    0.0364    
50% 33 (49.2)     
 <50% 34 (50.7) 31.0   1.308 0.430–3.978 0.636
  1. Abbreviations: CI=confidence interval; HR=hazard ratio; JCGC=Japanese Gastric Cancer Association; MST=median survival time; OS=overall survival.